merged_novo-nordisk-earnings-ozempic-wegovy.txt
<other>Determining if the article provides specific percentage of revenue from obesity drugs in the US in the second half of 2024.</other>
<question_number>1</question_number>
<answer>N/A</answer>
<other>Checking the number of consecutive quarters Novo Nordisk maintained its position as Europe's most valuable company.</other>
<question_number>2</question_number>
<answer>N/A</answer>
<other>Looking for information on other European countries manufacturing semaglutide besides Denmark.</other>
<question_number>3</question_number>
<answer>N/A</answer>
<other>Assessing if the article mentions the total market capitalization when stock peaked in June 2024.</other>
<question_number>4</question_number>
<answer>N/A</answer>
<other>Verifying the number of patients in the late-stage CagriSema trial.</other>
<question_number>5</question_number>
<answer>N/A</answer>
<other>Checking for revenue targets predicted by Emily Field for obesity drugs by 2030.</other>
<question_number>6</question_number>
<answer>N/A</answer>
<other>Identifying the number of manufacturing facilities Novo Nordisk operates in the US.</other>
<question_number>7</question_number>
<answer>N/A</answer>
<other>Looking for percentages of prescriptions written by primary care physicians versus specialists.</other>
<question_number>8</question_number>
<answer>N/A</answer>
<other>Determining the dollar value of Danish pharmaceutical exports affected by Trump's tariffs.</other>
<question_number>9</question_number>
<answer>N/A</answer>
<other>Assessing the duration of the amycretin early-stage trial.</other>
<question_number>10</question_number>
<answer>N/A</answer>
<other>Calculating the implied conversion rate of Danish kroner to US dollars.</other>
<question_number>11</question_number>
<answer>0.14</answer>
<other>Identifying the next-generation weight loss drug mentioned in the article.</other>
<question_number>12</question_number>
<answer>CagriSema</answer>
<other>Determining the major political event contributing to uncertainties in obesity drug sales.</other>
<question_number>13</question_number>
<answer>President Trump's election</answer>
<other>Identifying the Danish pharmaceutical company's home country implicated by tariffs.</other>
<question_number>14</question_number>
<answer>Denmark</answer>
<other>Finding the lowest percentage growth forecasted for 2025 revenue performance.</other>
<question_number>15</question_number>
<answer>16%</answer>
<other>Reflecting on the percentage decline from peak in June.</other>
<question_number>16</question_number>
<answer>40%</answer>
<other>Counting the number of obesity drugs explicitly named in the article.</other>
<question_number>17</question_number>
<answer>4</answer>
<other>Identifying the market that primarily drove the revenue jump.</other>
<question_number>18</question_number>
<answer>United States</answer>
<other>Determining which economic bloc the U.S. President warned would face tariffs.</other>
<question_number>19</question_number>
<answer>European Union</answer>
<other>Identifying the overarching volatile factor affecting growth outlook.</other>
<question_number>20</question_number>
<answer>Geopolitics</answer>